Article

InSite Vision, FDA discuss probable NDA for ocular anti-infective

InSite Vision representatives said they met recently with FDA officials to discuss sections of the proposed new drug application (NDA) submission for AzaSite, InSite's ocular anti-infective product. The drug is currently in late-stage development for the treatment of bacterial conjunctivitis.

InSite Vision representatives said they met recently with FDA officials to discuss sections of the proposed new drug application (NDA) submission for AzaSite, InSite's ocular anti-infective product. The drug is currently in late-stage development for the treatment of bacterial conjunctivitis.

The company said it anticipates launching AzaSite commercially in the United States in the second half of 2006, pending successful completion of and satisfactory results from current ongoing phase III clinical trials and subsequent filing of the full NDA and approval from the FDA.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
© 2025 MJH Life Sciences

All rights reserved.